Company news
Hunan Nucien Pharmaceutical Co. Ltd. news in 2026
Hunan Nucien Pharmaceutical Co. Ltd.'s news releases, calls and decks from 2026, newest first.
(688189)"Hunan Nucien Pharmaceutical Co., Ltd."Indicative Announcement on Change in Equity Interests of Shareholder Holding More Than 5% of the Shares Reaching 1% Threshold
November 19, 2026
(688189)"Hunan Nucien Pharmaceutical Co., Ltd."Report for Q3 2026
October 30, 2026
(688189)"Hunan Nucien Pharmaceutical Co., Ltd."Announcement on Convening the Q3 2026 Performance Briefing
October 30, 2026
(688189)"Hunan Nucien Pharmaceutical Co., Ltd."Indicative Announcement on Change in Equity Interests of Shareholder Holding More Than 5% of the Shares Reaching 1% Threshold
October 23, 2026
(688189)"Hunan Nucien Pharmaceutical Co., Ltd."Announcement on Amendment to the Articles of Association, Change of Legal Representative and Completion of Industrial and Commercial Registration Changes
October 23, 2026
(688189)"Hunan Nucien Pharmaceutical Co., Ltd."Announcement on Temporary Use of Certain Idle Raised Funds to Supplement Working Capital
October 9, 2026
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
September 22, 2026
Announcement on Election of New Board of Directors
September 4, 2026
Announcement on Shareholding Reduction Plan of Shareholder
September 2, 2026
Announcement on Progress of the Transfer of Certain Accounts Receivable and Related Party Transactions
August 31, 2026
Announcement on Convening the 2026 Semi-annual Performance Briefing
August 30, 2026
Announcement on Attending the 2026 Online Collective Reception Day for Investors of Listed Companies in Hunan Jurisdiction and Semi-annual Performance Briefing
August 25, 2026
Announcement on Appointment of General Manager
August 21, 2026
Announcement on the Receipt of Warning Letters by the Company and Relevant Responsible Persons
August 13, 2026
Announcement on Reduction of Registered Capital, Amendment of the Articles of Association, and Completion of Industrial and Commercial Registration Changes
August 10, 2026
Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report
July 15, 2026
Announcement on Abnormal Fluctuations in Stock Trading
July 14, 2026
Announcement on Implementing Cancellation of Repurchased Shares and Share Changes
July 8, 2026
Announcement on Receipt of Drug Registration Acceptance Notice
June 22, 2026
Announcement on Progress in the Strategic Restructuring of Controlling Shareholders
June 17, 2026
Announcement on Obtaining Drug Registration Certificate for Levosalbutamol Hydrochloride Nebuliser Solution
June 16, 2026
Announcement on Voluntary Disclosure of Phase III Clinical Trial of Peramivir Inhalation Solution Reaching Prespecified Primary Endpoint
June 11, 2026
Announcement on Receiving the Prior Notice of Administrative Penalty
June 9, 2026
Announcement on Progress in Transfer of Partial Accounts Receivable and Related Party Transactions
June 1, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
May 22, 2026
Indicative Announcement on the Controlling Shareholder's Planning of Strategic Restructuring
May 14, 2026
Announcement on Changing Purpose of Repurchased Shares Canceling and Reducing Registered Capital, and Amending the "Articles of Association"
April 29, 2026
Announcement on Resignation of Core Technical Personnel
April 24, 2026
Announcement on Progress in Public Listing and Transfer of Partial Accounts Receivable
April 15, 2026
Announcement on Progress in Repurchasing Shares through Call Auction
April 1, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 27, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
February 11, 2026
Announcement on Expected Loss in Performance for 2025
January 30, 2026
Announcement on By-electing an Independent Director and Adjusting Members of Partial Special Committees
January 26, 2026
Announcement on Resignation of Independent Director
January 4, 2026